§ Claim under review · Mixed
"Researchers at Osaka University in Japan have identified a drug called IU1 that can significantly slow aging by enhancing the protein quality control systems in cells and may even open the door to extending human life up to 250 years."
Verdict
Partially accurate but misleading
Confidence
Not recordedSummary
The viral post gets several important things wrong. The drug IU1 is real and there is a real 2024 peer-reviewed study showing it boosts cellular cleanup systems (proteasome and autophagy) and extends lifespan, but that research was done at Chung-Ang University in South Korea, not Osaka University in Japan. The experiments were performed in fruit flies and cultured human cells, not living humans. The linked Osaka University paper is a separate study about a different protein called AP2A1 and does not involve IU1 at all. The claim that IU1 could extend human life to 250 years appears in no primary source and is a viral exaggeration added by aggregator sites. No IU1 human clinical trials for aging exist.
The readings
key figures from the evidenceClaimed human lifespan extension from IU1 (fabricated figure)
Why this verdict
Evidence
The viral post conflates two separate studies from two different countries and adds a "250-year" figure that appears in neither.
Study A (the actual IU1 study, from Korea, not Japan): The researchers led by Professor Seogang Hyun from Chung-Ang University, Korea, identified a drug that could extend lifespan . Inhibiting the activity of ubiquitin specific peptidase 14 (USP14), a component of the proteasome complex, with IU1 enhanced not only proteasome activity but also autophagy activity simultaneously . The experimental subjects were fruit flies , with confirmatory work in human cells in a dish, not in living humans.
Study B (the Osaka University study the user linked, which does NOT involve IU1): Researchers from Osaka University found that knockdown of the Adaptor Protein Complex 2, Alpha 1 Subunit (AP2A1) rejuvenates aging cells, while AP2A1 overexpression ages young cells . This study is about a completely different mechanism (AP2A1 and cytoskeletal stress fibers) and does not mention IU1, proteasomes, or autophagy as the primary intervention.
The "250 years" figure: Does not appear in either peer-reviewed paper or either institution's press release. It was added by downstream aggregator sites and social media accounts. A fact-check circulating on X notes that the 250-year figure is speculative exaggeration, not a direct or proven outcome. No such drug is ready for human use .
Findings
✓ What's accurate 9
- IU1 is a real compound (a USP14 inhibitor).
- A real study did show IU1 boosts both proteasome activity and autophagy simultaneously.
- The study did report extended lifespan and reduced muscle weakness in fruit flies.
- Osaka University did publish a separate, unrelated 2025 study on cellular rejuvenation involving the AP2A1 protein. ## WHAT IS MISLEADING OR FALSE
- **Fabricated attribution:** The IU1 study is from **Chung-Ang University in South Korea**, not Osaka University in Japan. The researchers led by Professor Seogang Hyun from Chung-Ang University, Korea conducted this work.
- **Conflation of two studies:** The viral post pastes together the IU1/Korea study with a completely separate Osaka University study on the AP2A1 protein, presenting them as a single Japanese discovery.
- **Species extrapolation:** Results in fruit flies and cells in a dish are presented as applicable to humans. IU1 has never been tested for lifespan extension in humans.
- **Fabricated "250 years" figure:** This number appears in neither peer-reviewed paper nor either institution's official press release. It is a viral embellishment. The 250-year figure is speculative exaggeration, not a direct or proven outcome .
- **Exaggeration/marketing language:** Phrases like "significantly slow aging" and "open the door to extending human life" overstate what preclinical fruit fly and cell-culture evidence can support.
? What's uncertain 2
- Whether IU1 or any USP14 inhibitor will translate to safe, effective lifespan or healthspan extension in humans (no human trials exist).
- Long-term safety profile of IU1 in mammals. ---
Sources
3 of 5 linked to records**Kim et al. (2024), "Pharmacological inhibition of USP14 delays proteostasis-associated aging in a proteasome-dependent but foxo-independent manner," Autophagy journal.** Primary source. Peer-reviewed. https://www.tandfonline.com/doi/full/10.1080/15548627.2024.2389607
**Chung-Ang University press release via EurekAlert! (Sept 2024).** Primary institutional source. https://www.eurekalert.org/news-releases/1059194
**Yamada et al. (2025), "AP2A1 modulates cell states between senescence and rejuvenation," Cellular Signalling** (the DOI S0898656825000294 the user cited). Primary source, unrelated to IU1. https://www.sciencedirect.com/science/article/pii/S0898656825000294
**Osaka University press release, "A newly discovered mechanism rejuvenates aging cells" (EurekAlert!).** Primary institutional source, unrelated to IU1. https://www.eurekalert.org/news-releases/1074056
**SciTechDaily coverage of the AP2A1 study**, cited in the viral post. Secondary. https://scitechdaily.com/scientists-discover-key-protein-that-may-reverse-aging-at-the-cellular-level/